Fight Cancer With Our Breakthrough Drug Prediction Platform – DxPP
Fight Cancer With Our Breakthrough Drug Prediction Platform – DxPP
Discover the difference our first-in-kind AI and therapy resistant cell technologies bring to treatment planning and drug development for cancer patients.
Discover the difference our first-in-kind AI and therapy resistant cell technologies bring to treatment planning and drug development for cancer patients.
First Ascent’s Ex Vivo Drug Response Identification & Validation Engine – xDRIVE Platform is a first-in-kind medical oncology decision support system that integrates functional drug testing, DNA/RNA sequencing and AI-guided tumor weakness mapping resulting in prioritized therapeutic solutions tailored to the patient’s tumor vulnerabilities and validated through tests run on the patient’s own cells.
Publication and Pharma Partners
The Latest First Ascent Biomedical News
Our study shows the technical feasibility of integrating functional precision medicine approaches for patients with [...]
Our studies demonstrate the potential for predictive and generative artificial intelligence and machine learning approaches [...]
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its [...]